Patients with rheumatoid arthritis are at an increased risk for venous thromboembolism, regardless of age, sex, BMI, and ...

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in ...

A declining stock price amid steadily rising payouts means Realty Income stock offers an above-average yield of 5.5% at ...

An experimental Pfizer sickle cell treatment failed to meet the main goal in a late-stage trial for patients aged 16 and ...

President Trump wrote to major drug companies, informing them that they had to comply with his “Most Favored Nation” order.

Mixed options sentiment in Pfizer (PFE), with shares up 2c, or 0.1%, near $25.16. Options volume relatively light with 28k contracts traded and ...

The U.S. government announced funding cuts to mRNA vaccine research. What is the impact on American healthcare and biotech?

Crescent Biopharma is an early-stage biotech with a promising PD-1/VEGF bispecific antibody. Read why I rate CBIO stock as a ...